Quoin Pharmaceuticals (QNRX) Projected to Post Earnings on Thursday

Quoin Pharmaceuticals (NASDAQ:QNRX) is projected to post its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect the company to announce earnings of ($6.42) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Tuesday, March 10, 2026 at 4:00 PM ET.

Quoin Pharmaceuticals Stock Down 2.7%

Shares of QNRX opened at $8.50 on Thursday. The firm has a market cap of $7.14 million, a PE ratio of -0.27 and a beta of 1.60. The company’s fifty day moving average is $10.10 and its two-hundred day moving average is $11.04. Quoin Pharmaceuticals has a fifty-two week low of $5.01 and a fifty-two week high of $41.80.

Institutional Investors Weigh In On Quoin Pharmaceuticals

Several hedge funds have recently modified their holdings of QNRX. Ikarian Capital LLC acquired a new position in Quoin Pharmaceuticals during the 4th quarter worth approximately $3,052,000. Millennium Management LLC purchased a new stake in shares of Quoin Pharmaceuticals during the fourth quarter valued at approximately $1,080,000. SummitTX Capital L.P. purchased a new position in shares of Quoin Pharmaceuticals in the fourth quarter valued at $935,000. Boothbay Fund Management LLC purchased a new position in shares of Quoin Pharmaceuticals in the fourth quarter valued at $863,000. Finally, ADAR1 Capital Management LLC acquired a new stake in Quoin Pharmaceuticals during the 4th quarter valued at $840,000. 8.63% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

QNRX has been the subject of a number of research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Quoin Pharmaceuticals in a research report on Monday, December 22nd. Wall Street Zen upgraded Quoin Pharmaceuticals to a “sell” rating in a report on Saturday, November 15th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Quoin Pharmaceuticals Company Profile

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc The company was founded in 2018 and is based in Ashburn, Virginia.